Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00332618
Other study ID # Laboratoires CARILENE
Secondary ID
Status Completed
Phase Phase 2
First received May 31, 2006
Last updated June 6, 2006
Start date September 2003
Est. completion date April 2004

Study information

Verified date March 2003
Source Laboratoires CARILENE
Contact n/a
Is FDA regulated No
Health authority France: Ministry of HealthUnited States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The objective of the trial was to evaluate the efficacy and clinical safety and acceptability of Oxygenated Glycerol Triesters in the relief of symptoms of xerostomia versus a reference comparator.


Description:

Xerostomia is due to inadequate (hyposialia) or inexistent (asialia) saliva secretion.

There are may causes. Transitory xerostomia may occur in the presence of anxiety (stage fright, fear or dehydration). Prolonged xerostomia is most often related to a systemic disease, certain medicines or to radiotherapy of the head or neck.

Salivation depends upon the autonomic (sympathetic and parasympathetic) nervous system for its production and on the central nervous system for stimuli-dependant excretion. Substances acting on alpha an beta sympathetic receptors, whether agonists or antagonists, may induce hyposialia. Atropine, the main antagonist of the parasympathetic system, is present in many medicines used for pulmonary, ophthalmic or neurological purposes, potentially causing hyposialia. Similarly, imipramine antidepressants, phenothiazine neuroleptics, antihistamines and disopyramide predispose to the onset of hyposialia.

Xerostomia is often accompanied by buccal signs such as impaired sense of taste, halitosis and buccal ulcers and interferes with functions such as speech, chewing and swallowing. Because of reduced salivary secretion , there is a disturbance of the microbial colonization of the buccal cavity. Xerostomia has significant untoward effects on the buccal cavity and the quality of life of patients.

The basis of the treatment of xerostomia involves the use of saliva substitutes and/or saliva stimulants. Oxygenated Glycerol Triesters is neither a replacement for nor stimulant of saliva. It is a lubricant and protective solution for endobuccal spray.


Recruitment information / eligibility

Status Completed
Enrollment 74
Est. completion date April 2004
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- men or women over 18 years of age

- with a diagnosis requiring the prescription of psychotropies (antidepressants, tranquilizers, etc) for more than 6 weeks

- having received no palliative treatment for xerostomia for a minimum of the past 2 weeks

- having xerostomia meeting the questionnaire selection criteria and the sialometer method parameters

- patients legally competent to give their consent

- capable of and accepting to participate in the trial and capable of and accepting to answer trial questionnaires

Exclusion Criteria:

- combined treatments incompatible with the trial, un particular alcoholic solutions

- diabetes, any buccal condition requiring antimicrobial treatment

- Sjögren's syndrome or othermedical causes of xerostomia

- current participation in other clinical trials

- patient suffering from cancer

- patients with allergy to or known intolerance of any of the constituents of the investigational products

- patients treated with pilocarpine

Study Design

Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


Intervention

Device:
OXYGENATED GLYCEROL TRIESTERS


Locations

Country Name City State
France Chu Hopital Des Broussailles Cannes

Sponsors (1)

Lead Sponsor Collaborator
Laboratoires CARILENE

Country where clinical trial is conducted

France, 

References & Publications (1)

Fox PC. Management of dry mouth. Dent Clin North Am. 1997 Oct;41(4):863-75. Review. — View Citation

See also
  Status Clinical Trial Phase
Completed NCT05342272 - Comparison of Gum® HydralTM Moisturizing Gel and Biotene® Oral Gel in Dry Mouth Sensation Reduction Phase 3
Completed NCT03302676 - The Use of Chewing Gum for Xerostomia and Hyposalivation After Radiotherapy for Oral and Oropharyngeal Tumors N/A
Completed NCT02375451 - Effect of Childhood Radioiodine Therapy on Salivary Function N/A
Completed NCT01272570 - Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors N/A
Completed NCT00656513 - Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Phase 2/Phase 3
Completed NCT00911768 - Effect of Korean Red Ginseng (KRG) on Dry Mouth Phase 4
Completed NCT03494985 - A Clinical Study to Evaluate the Efficacy of Three Dry Mouth Relief Products Versus Water N/A
Completed NCT05058430 - SaliPen Human Factors Study for OTC Labeling N/A
Recruiting NCT02705937 - Early Phase Study Comparing the Effectiveness of a Dairy Product With the Reference Treatment Aequasyal® on Dry Mouth Symptoms in Patients Suffering From Xerostomia Caused by Psychotropic Medications. N/A
Completed NCT05247008 - Effectiveness of Thyme Honey in Management of Xerostomia in ESRD N/A
Recruiting NCT03632096 - Photobiomodulation in Salivary Production of Patients With Xerostomy Phase 2
Not yet recruiting NCT04323384 - The Effect of Biotene® on the Symptoms of Xerostomia and Mastication and Swallowing N/A
Not yet recruiting NCT03530735 - Finger-prick Autologous Blood (FAB) for Use in Dry Mouth N/A
Active, not recruiting NCT03176368 - Coconut Oil: Managing Radiation-Induced Xerostomia N/A
Enrolling by invitation NCT06122636 - Efficacy of a Probiotic and Microbiological Analysis on Oral Complications Induced by Antineoplastic Therapies in Patients With HNC N/A
Completed NCT03611283 - Topical Management of Xerostomia With Dry Mouth Products N/A
Completed NCT02682199 - Prospective Evaluation of Patient Reported Xerostomia After Whole Brain Radiation
Withdrawn NCT01960101 - Development of a Milk Product Substitution for Patients Suffering From Xerostomia Caused by Medication N/A
Completed NCT02317172 - Efficacy of Novel Edible Gel-based Artificial Saliva in Thai Geriatric Populations With Systemic Diseases N/A
Completed NCT00350350 - OGT Spray in the Management of Xerostomia in the Elderly Phase 3